Medeze Group PCL (BKK:MEDEZE) ROCE %: 5.20% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:MEDEZE Medeze Group PCL BKK:MEDEZE
19 GF Score
Price ฿6.20
! 5 Warning Signs
View Full Analysis

What is Medeze Group PCL ROCE %?

Medeze Group PCL BKK:MEDEZE -1.59% 19 ROCE % is 5.20% as of Jun. 2026. GuruFocus rates BKK:MEDEZE with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medeze Group PCL's annualized ROCE % for the quarter that ended in Jun. 2026 was 5.20%.

Medeze Group PCL  (BKK:MEDEZE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medeze Group PCL ROCE % Related Terms

Medeze Group PCL ROCE % Historical Data

* Premium members only.

The historical data trend for Medeze Group PCL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeze Group PCL ROCE % Chart

Medeze Group PCL Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
39.44 18.50 7.55

Medeze Group PCL Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 8.65 4.84 4.99 4.61 5.20
BKK:MEDEZE
19GF Score
Medeze Group PCL BKK:MEDEZE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeze Group PCL ROCE % Calculation

Medeze Group PCL's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=250.877144/( ( (3429.038729 - 124.658937) + (3478.123794 - 136.838231) )/ 2 )
=250.877144/( (3304.379792+3341.285563)/ 2 )
=250.877144/3322.8326775
=7.55 %

Medeze Group PCL's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=176.992/( ( (3538.947 - 118.742) + (3488.895 - 100.355) )/ 2 )
=176.992/( ( 3420.205 + 3388.54 )/ 2 )
=176.992/3404.3725
=5.20 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.20% mean?
Medeze Group PCL (BKK:MEDEZE) has a ROCE % of 5.20% as of Jun. 2026.
Is Medeze Group PCL's ROCE % too high?
Medeze Group PCL's current ROCE % is 5.20%. The Healthcare Providers & Services industry median ROCE % is 6.32. Medeze Group PCL's value of 5.20% is 17.7% below this industry median. Overall, Medeze Group PCL has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medeze Group PCL's ROCE % compare to HCA and THC?
Medeze Group PCL's ROCE % of 5.20% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.32. Medeze Group PCL's value of 5.20% is 17.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.32, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeze Group PCL's current ROCE % of 5.20% is 17.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeze Group PCL's current ROCE % is 5.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeze Group PCL stock overvalued right now?
Medeze Group PCL (BKK:MEDEZE) has a current ROCE % of 5.20%. The current ROCE % is 5.20% and 17.7% below the Healthcare Providers & Services industry median of 6.32. Medeze Group PCL's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medeze Group PCL (BKK:MEDEZE), the current ROCE % is 5.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medeze Group PCL Business Description

Address Phuttha Monthon Sai 4 Road, 28/9 Moo 8, Krathum Lom, Sam Phran, Nakhon Pathom, THA, 73220
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.
19GF Score

Get the complete analysis for BKK:MEDEZE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿6.20
Price